Trial Profile
A Single Blind, Randomised, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK206136 in Healthy Male Subjects and an Open Label Positron Emission Tomography Study to Evaluate the Serotonin Transporter and Neurokinin-1 Receptor Occupancy.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Sep 2023
Price :
$35
*
At a glance
- Drugs GSK 206136 (Primary)
- Indications Anxiety disorders; Depressive disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GSK
- 06 Feb 2010 New trial record